Home Improvement of a prenatal screening program for trisomy 18 in the first trimester of gestation
Article
Licensed
Unlicensed Requires Authentication

Improvement of a prenatal screening program for trisomy 18 in the first trimester of gestation

  • Eduardo Martínez-Morillo , Belén Prieto EMAIL logo , Francisco Moreno and Francisco V. Álvarez
Published/Copyright: May 25, 2012

Abstract

Background: The aim of this study was to evaluate population parameters (medians, standard deviations and coefficients of correlation) different from those used by the commercial software Elipse® v3.0 (Perkin Elmer) in the calculation of prenatal risk of trisomy 18. Moreover, the truncation limits used for extreme values of free β-human chorionic gonadotropin (fβ-hCG), pregnancy associated plasma protein-A (PAPP-A) and nuchal translucency (NT) were revised.

Methods: A calculation engine for the prenatal risk of trisomy 18 was developed [called FMF (Fetal Medicine Foundation) calculator]. Recently, published population parameters for fβ-hCG and PAPP-A as well as new truncation limits were included in this calculator. The patient-specific risks obtained by Elipse® v3.0 and FMF calculators, were compared in 18,801 pregnant women, including 13 cases of trisomy 18, four cases of trisomy 13 and one case of triploidy.

Results: Using a cut-off point of 1:250, FMF calculator increased the detection rate of trisomy 18 from 62% to 100% with a 0.31% increase in the false-positive rate (FPR). When the detection rate was fixed at 100%, the FPR generated by Elipse v3.0 (1.52%) was significantly higher (p<0.0001) than that generated by the FMF calculator (0.36%). Moreover, an improved detection in cases of trisomy 13 and triploidy was observed.

Conclusions: It is recommended that each laboratory reviews the population parameters and truncation limits used in the risk calculation of trisomy 18, in order to obtain an adequate performance in the screening.


Corresponding author: Belén Prieto, PhD, Hospital Universitario Central de Asturias, C/Celestino Villamil, s/n – 33006 Oviedo, Spain Phone/Fax: +34 985 108073

Received: 2011-12-14
Accepted: 2012-05-03
Published Online: 2012-05-25
Published in Print: 2012-11-01

©2012 by Walter de Gruyter Berlin Boston

Articles in the same Issue

  1. Congress Abstracts
  2. 44th National Congress of the Italian Society of Clinical Biochemistry and Clinical Molecular Biology
  3. Masthead
  4. Masthead
  5. Editorials
  6. Tumor biomarkers: PSA and beyond
  7. Error reporting in transfusion medicine: an important tool to improve patient safety
  8. The measurement of 25-hydroxy vitamin D – an analytical challenge
  9. Reviews
  10. Kallikrein-related peptidases (KLKs): a gene family of novel cancer biomarkers
  11. Exhaled breath analysis for early cancer detection: principle and progress in direct mass spectrometry techniques
  12. γ′ Fibrinogen as a novel marker of thrombotic disease
  13. Mini Review
  14. Revaluating serum ferritin as a marker of body iron stores in the traceability era
  15. Genetics and Molecular Diagnostics
  16. Association of PBEF gene polymorphisms with acute lung injury, sepsis, and pneumonia in a northeastern Chinese population
  17. General Clinical Chemistry and Laboratory Medicine
  18. Brazilian laboratory indicators program
  19. Error reporting in transfusion medicine at a tertiary care centre: a patient safety initiative
  20. Application of mathematical models of system uncertainty to evaluate the utility of assay calibration protocols
  21. 25-Hydroxyvitamin D testing: challenging the performance of current automated immunoassays
  22. Analytical validation of the Roche 25-OH Vitamin D Total assay
  23. The new Roche Vitamin D Total assay: fit for its purpose?
  24. Improvement of a prenatal screening program for trisomy 18 in the first trimester of gestation
  25. Stability of osteopontin in plasma and serum
  26. Is there a suitable point-of-care glucose meter for tight glycemic control? Evaluation of one home-use and four hospital-use meters in an intensive care unit
  27. Cancer Diagnostics
  28. Rapid elimination kinetics of free PSA or human kallikrein-related peptidase 2 after initiation of gonadotropin-releasing hormone-antagonist treatment of prostate cancer: potential for rapid monitoring of treatment responses
  29. Detection of frequent ABCB1 polymorphisms by high-resolution melting curve analysis and their effect on breast carcinoma prognosis
  30. Cardiovascular Diseases
  31. The combined use of neutrophil gelatinase-associated lipocalin and brain natriuretic peptide improves risk stratification in pediatric cardiac surgery
  32. Association of the atherogenic index of plasma and oxidative stress status with weight gain during non-complicated pregnancy
  33. The high-sensitivity cardiac troponin T assay is superior to its previous assay generation for prediction of 90-day clinical outcome in ischemic stroke
  34. Letters to the Editor
  35. Evaluation of the cross-reactivity of 25-hydroxyvitamin D2 on seven commercial immunoassays on native samples
  36. Measurement of 25-hydroxyvitamin vitamin D by liquid chromatography tandem-mass spectrometry with comparison to automated immunoassays
  37. Analytical evaluation of a new automated protein binding assay to determine 25-hydroxyvitamin D concentrations
  38. Mindray BS-800M1: a new clinical chemistry system with a flexible technology meeting quality performances
  39. Association of urinary albumin and serum high molecular weight-adiponectin with metabolic syndrome in patients with essential hypertension
  40. Measurement of nitrite in plasma and serum: still a challenging analytical task
  41. Association between serum γ-glutamyltransferase and pulmonary dysfunction
  42. Serum ferritin concentrations predict incidence of metabolic syndrome in rural Korean adults
  43. Homocysteine, folic acid and vitamin B12 levels in females with severe acne vulgaris
Downloaded on 8.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/cclm-2012-0198/html
Scroll to top button